Abstract: This disclosure provides an encapsulated cleansing composition that is free of talc and that includes a core particle including (1) tapioca starch, (2) potato starch, (3) at least one anionic surfactant, and (4) at least one amphoteric surfactant. The encapsulated cleaning composition also includes a coating disposed about at least a portion of the core particle and includes a polysaccharide.

Abstract: Methods for making a personal care product and a personal care product are provided. In one example, the method includes forming a first layer by an additive process. The first layer has a first composition that includes at least one filler component selected from the group of starch, bulking agent salt, granular acid, clay mineral, sorbitol, silica, titanium dioxide, and zinc oxide. A binder is applied to the first layer. A second layer is formed by the additive process overlying the binder. The second layer has a second composition that includes at least one filler component selected from the group of starch, bulking agent slat, granular acid, clay mineral, sorbitol, silica, titanium dioxide, and zinc oxide. At least one of the first composition and the second composition further includes at least one surfactant.

Abstract: A conditioning composition is free of talc and includes tapioca starch, optionally potato starch, optionally corn starch, at least one anionic surfactant, and optionally at least one amphoteric surfactant, which may be described as a core particle. The conditioning composition may include, or be free of, a coating disposed about at least a portion of the core particle and having a compound chosen from cellulose polymers, anionic or cationic polymers, vinyl polymers, natural polymers, polysaccharides, copolymers thereof, and combinations thereof. The conditioning composition includes from about 0 to about 25 percent by weight of liquid, has a pH of from about 3.5 to about 5 when mixed with water at about 10 wt % and produces a flash foam of less than about 10 ml when contacted with water at a temperature of about 26 to about 30° C. degrees.

Abstract: Solid concentrated compositions of foaming cleansers, methods for preparing such solid concentrated compositions, and methods for forming liquid cleansing solutions from such solid concentrated compositions are provided. An exemplary solid concentrated composition includes a surfactant and a dissolution promotion agent, wherein the composition is anhydrous, and wherein the composition is substantially free of sulfates.

Abstract: Provided herein are modified adeno-associated viral (AAV) capsid proteins, compositions (e.g., rAAV) comprising the capsid proteins, and nucleic acids encoding the capsid proteins. The AAV capsids provided herein confer retinal cell tropism and/or corneal cell tropism, and mediate improved transduction efficiency in clinically relevant ocular cell types such as photoreceptors and/or corneal endothelial cells. Also provided are nucleic acids encoding the capsid proteins, and AAV particles comprising the capsid proteins.

Abstract: Provided herein are improved rAAV (e.g., rAAV2, rAAVrh8R, etc.) for enhanced gene therapy of ocular disorders or CNS disorders wherein the rAAV comprise one or more substitutions of amino acids that interact with heparan sulfate proteoglycan. The invention provides methods for improved transduction of retinal cells and methods for treating ocular diseases with improved compositions of rAAV particles. Further provided herein are improved recombinant adeno-associated virus (rAAV) (e.g., rAAV2, rAAVrh8R, etc.) for enhanced gene therapy of disorders of the CNS. The invention provides methods for delivering the rAAV to the CNS, methods for treating disorders of the CNS with improved compositions of rAAV particles, and kits for delivering the rAAV to the CNS and/or treating a CNS disorder.

Abstract: Provided herein are improved rAAV (e.g., rAAV2, rAAVrh8R, etc.) for enhanced gene therapy of ocular disorders or CNS disorders wherein the rAAV comprise one or more substitutions of amino acids that interact with heparan sulfate proteoglycan. The invention provides methods for improved transduction of retinal cells and methods for treating ocular diseases with improved compositions of rAAV particles. Further provided herein are improved recombinant adeno-associated virus (rAAV) (e.g., rAAV2, rAAVrh8R, etc.) for enhanced gene therapy of disorders of the CNS. The invention provides methods for delivering the rAAV to the CNS, methods for treating disorders of the CNS with improved compositions of rAAV particles, and kits for delivering the rAAV to the CNS and/or treating a CNS disorder.

Abstract: Provided herein are improved rAAV (e.g., rAAV2, rAAVrh8R, etc.) for enhanced gene therapy of ocular disorders or CNS disorders wherein the rAAV comprise one or more substitutions of amino acids that interact with heparan sulfate proteoglycan. The invention provides methods for improved transduction of retinal cells and methods for treating ocular diseases with improved compositions of rAAV particles. Further provided herein are improved recombinant adeno-associated virus (rAAV) (e.g., rAAV2, rAAVrh8R, etc.) for enhanced gene therapy of disorders of the CNS. The invention provides methods for delivering the rAAV to the CNS, methods for treating disorders of the CNS with improved compositions of rAAV particles, and kits for delivering the rAAV to the CNS and/or treating a CNS disorder.

Abstract: A lockable hinge for use in orthopedic braces is provided. When used in a knee brace, the present hinge provides a knee-immobilizing brace that assists persons with standing and/or walking. The hinge is easily converted from a locked mode to a free range of motion mode and vice versa. When the hinge is in the locked mode, patients are better able to stand and walk. With the push of a button, the patient can bend his or her knee to sit or lie down more comfortably. When the hinge is in the free range of motion mode, patients are better able to participate in physical therapy activities without the hinge locking.

Abstract: An osteoarthritis brace having relatively large semi-rigid cuffs for abutting the wearer's thigh and calf. In one embodiment, the semi-rigid cuffs are secured to rigid cuffs of the brace only on one side and in substantially a center of the rigid cuffs. The semi-rigid cuffs bear reaction forces created by a medial/lateral force applied to the wearer's knee by a hinge of the brace. The semi-rigid cuffs provide flesh containment, distribute loads over a large portion of the wearer's flesh, eliminate pinch points and provide enhanced fitting capabilities.

Abstract: An osteoarthritis brace having relatively large semi-rigid cuffs for abutting the wearer's thigh and calf. In one embodiment, the semi-rigid cuffs are secured to rigid cuffs of the brace only on one side and in substantially a center of the rigid cuffs. The semi-rigid cuffs bear reaction forces created by a medial/lateral force applied to the wearer's knee by a hinge of the brace. The semi-rigid cuffs provide flesh containment, distribute loads over a large portion of the wearer's flesh, eliminate pinch points and provide enhanced fitting capabilities.

Abstract: A method and apparatus for establishing a large number of EDTOV timers, each determining when an event has failed to occur on an exchange of a communications protocol. Values for each timer are maintained as a timer array. The entire timer array is read at regular scan intervals by a state machine and decremented by four associated hardware decrementers, four timers at one time. A Scan Interval variable determines the scan interval. The present invention is capable of scan intervals of up to 100 ns. Active time values are read, checked for zero, decremented preferably by one, and written back to the timer array. If a timer is detected as having timed out (equal to zero), then a value which identifies the exchange associated with that timer is logged into a time-out FIFO and "FF"h is written back into the timer.